Oral oxytocin antagonists.
Borthwick
Alan D
AD
DrugMolDesign, 15 Temple Grove, London NW117UA, UK. alan.d.borthwick@drugmoldesign.com
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D002164:Camphor / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D010121:Oxytocin / Q000037:antagonists & inhibitors* / Q000737:chemistry; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D011487:Protein Conformation; D011759:Pyrrolidines / Q000737:chemistry / Q000494:pharmacology; D018045:Receptors, Oxytocin / Q000737:chemistry / Q000502:physiology; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology
D007211:Indoles; D010879:Piperazines; D010880:Piperidines; D011759:Pyrrolidines; D018045:Receptors, Oxytocin; D013449:Sulfonamides; D014230:Triazoles; D010121:Oxytocin; D002164:Camphor